18 results on '"*ANTIGEN receptors"'
Search Results
2. Understanding the Role of Bispecific Antibodies in the Management of B-Cell Non-Hodgkin Lymphoma: A New Immunotherapy That Is Here to Stay.
- Author
-
Ivanov, Stanislav, Muminovic, Meri, and Sandoval-Sus, Jose
- Subjects
- *
BISPECIFIC antibodies , *NON-Hodgkin's lymphoma , *HEMATOLOGIC malignancies , *CHIMERIC antigen receptors , *PATIENT experience - Abstract
Non-Hodgkin lymphomas (NHLs) represent a diverse group of hematologic malignancies derived from various cells. B-cell NHLs represent the largest fraction of lymphomas diagnosed and treated in the United States. Standard chemo-immunotherapies with rituximab and multiagent cytotoxic regimens have proven to be effective in the management of these lymphoproliferative neoplasms; nonetheless, a considerable fraction of patients still experience relapse or have treatment-refractory disease. Therapeutic advances using novel immunotherapeutic agents as well as cell-based treatments, such as chimeric antigen receptor (CAR) T-cell therapies, have improved the outcomes of relapsed/refractory (R/R) B-cell NHL. Most of these new treatment strategies are not curative and most patients succumb to R/R disease, leaving this population with an unmet need for effective and well-tolerated therapeutic options. One of these up-and-coming options are bispecific antibodies (BsAb), either as single agent or in combination with other medications. Conclusion: BsAbs offer a novel "off the shelf" chemotherapy-free approach in the management of R/R B-cell NHL. Advancements in antibody construct design along with improved safety profile and clinical effectiveness of the most recent BsAbs suggest that these agents are a promising new option in the management of R/R B-cell NHL. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy.
- Author
-
Katiyar, Vatsala, Chesney, Jason, and Kloecker, Goetz
- Subjects
- *
TREATMENT of lung tumors , *IMMUNE checkpoint inhibitors , *CELLULAR therapy , *CELL receptors , *LUNG tumors , *INDIVIDUALIZED medicine , *LYMPHOCYTES , *TREATMENT effectiveness - Abstract
Simple Summary: Lung cancer is the leading cause of cancer related mortality and morbidity in the United States and worldwide. The advent of Immunotherapy has significantly improved lung cancer prognosis. However, there is a huge unmet need for novel agents, as a significant number of patients do not have durable responses to immunotherapy. This review article highlights two such novel techniques—Chimeric antigen receptor (CAR) T-cell therapy and Tumor-infiltrating lymphocyte (TIL) therapy. Both these techniques utilize a patient's own immune cells to fight against tumors. While CAR T-cell therapy requires genetic modification of a patient's T cells to express receptors that can recognize and attack tumor cells rapidly, TILs involves extraction of immune cells from tumors and their proliferation in a laboratory before being infused back to the patient. Both these techniques are currently used in a clinical trial setting only. In this review, we discuss the limitations and future directions and potential for both these treatment strategies. Lung cancer is a leading cause of morbidity and mortality in the United States and worldwide. The introduction of immune checkpoint inhibitors has led to a marked improvement in the outcomes of lung cancer patients. Despite these advances, there is a huge unmet need for therapeutic options in patients who are not candidates for targeted or immunotherapy or those who progress after first-line treatment. With its high mutational burden, lung cancer appears to be an attractive target for novel personalized treatment approaches. In this review, we provide an overview of two adoptive cell therapy approaches–chimeric antigen receptors (CAR) T-cell therapy and Tumor-infiltrating lymphocytes (TILs) in lung cancer with an emphasis on current challenges and future perspectives. While both these therapies are still in the early phases of development in lung cancer and need more refinement, they harbor the potential to be effective treatment options for this group of patients with otherwise poor prognoses. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Immunotherapies in rare cancers.
- Author
-
Vivekanandhan, Sneha, Bahr, Deborah, Kothari, Ashish, Ashary, Mohammed Ali, Baksh, Mizba, and Gabriel, Emmanuel
- Subjects
- *
CHIMERIC antigen receptors , *THERAPEUTICS , *TREATMENT effectiveness , *IMMUNE checkpoint inhibitors , *CANCER treatment - Abstract
Cancer remains a leading cause of death worldwide, placing a significant burden on healthcare systems as well as the global economy. Rare cancers comprise a group of about 200 cancers that individually occur at extremely low frequencies. In the United States (US), their frequency is approximately 15 cases per 100,000 people, and it is even lower in Europe with approximately 6 cases per 100,000 people. However, combined their frequency of occurrence is much higher than any singular cancer. Cancer treatment and management has tremendously improved in the last decade, particularly with the administration of immune-based therapies. The four most prevalent immune-based therapies are (1) the use of immune-checkpoint inhibitors, (2) macrophage therapy, (3) Chimeric Antigen Receptor (CAR) T cell therapy, and (4) neoantigen-based therapies. In our review, we discuss these various aproaches and their implementation in the treatment of a variety of rare cancers. Furthermore, we discuss their limitations and potential strategies to overcome them to enhance the therapeutic efficacy of these approaches. Finally, our article presents the future directions and other additional immune therapies that may be incorporated into the treatment of rare cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Demographic differences among patients treated with chimeric antigen receptor T‐cell therapy in the United States.
- Author
-
Emole, Josephine, Lawal, Odunayo, Lupak, Oleksandra, Dias, Ajoy, Shune, Leyla, and Yusuf, Korede
- Subjects
- *
DEMOGRAPHIC characteristics , *CHIMERIC antigen receptors , *HOSPITAL mortality , *NON-Hodgkin's lymphoma , *RACE - Abstract
Background: It is not clear if all Americans have benefitted equally from the availability of chimeric antigen receptor T‐cell (CART) therapy. We aimed to evaluate if demographic differences existed among adult patients who received CART therapy and to assess predictors of CART treatment outcomes. Methods: Records of patients ≥18 years who received CART therapy for non‐Hodgkin's lymphoma, acute lymphoblastic leukemia, and multiple myeloma in 2018 were evaluated in the National Inpatient Sample. Acute complications and inhospital mortality were compared between two groups of CART recipients: Whites and non‐Whites. Logistic regression analysis was used to evaluate the association between sociodemographic factors and inhospital mortality. Results: Of 1275 CART recipients that met inclusion criteria, there were 40.4% of females, 66.9% of Whites, Blacks (4.2%), Hispanics (13.3%), Asians or Pacific Islanders (4.2%), and Native Americans (1.3%). Up to 96.8% of CART procedures were performed in urban teaching hospitals, and 85.3% of CART recipients lived in metropolitan counties. Non‐Whites, compared to Whites, were younger at the time of CART therapy (p < 0.001). The inhospital mortality rate was higher in non‐Whites, though not statistically significant (5.4% vs. 4.4%, p = 0.764). There were no differences in length of hospital stay, hospital charges, or rates of acute toxicities between the two race groups. We found no association between race and treatment outcomes. Gender, neurotoxicity, and Charlson Comorbidity Index were significant predictors of inhospital mortality. Conclusions: CART therapy recipients in the United States were more likely to be Whites and more likely to be residents of metropolitan areas. These observed demographic differences were not associated with treatment outcomes or inhospital mortalities. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.
- Author
-
Maziarz, Richard T., Yang, Hongbo, Liu, Qing, Wang, Travis, Zhao, Jing, Lim, Stephen, Lee, Soyon, Dalal, Anand, and Bollu, Vamsi
- Subjects
- *
DIFFUSE large B-cell lymphomas , *LENGTH of stay in hospitals , *DATA analysis , *CHIMERIC antigen receptors , *MEDICAL care - Abstract
This study compared the real-world healthcare resource utilization (HRU), costs, adverse events (AEs), and AE treatments associated with the chimeric antigen receptor T-cell (CAR-T) therapies, tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel), for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Adults with DLBCL who received tisa-cel or axi-cel were identified in the Premier Healthcare Database (2017–2020). Non-CAR-T costs, HRU, and AE rates during the infusion and follow-up periods were compared between the tisa-cel and axi-cel cohorts. Of 119 patients, 33 received tisa-cel (86% as inpatient infusion) and 86 received axi-cel (100% inpatient). Tisa-cel was associated with significantly shorter mean inpatient length of stay than axi-cel during infusion (11.3 vs. 18.3 days) and follow-up ([monthly] 3.9 vs. 6.9 days). Non-CAR-T costs were significantly lower for tisa-cel compared with axi-cel during infusion ($27594.8 vs. $51378.3) and follow-up ([monthly] $28777.3 vs. $46575.7; both p<.05). Rates of AEs and AE treatments were similar. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. CHARACTERIZATION OF HUMAN T CELLS AND NK CELLS EXPANDED WITH HUMAN PLATELET LYSATE FOR CHIMERIC ANTIGEN RECEPTOR BASED THERAPIES.
- Author
-
Alonso-Camino, V. and Mirsch, B.
- Subjects
- *
T cells , *KILLER cells , *CHIMERIC antigen receptors , *BLOOD platelets , *CELL suspensions , *EMERGING infectious diseases , *T cell receptors , *MANUFACTURING cells - Abstract
T cells and NK cells expressing chimeric antigen receptors (CAR) have demonstrated potent clinical efficacy in patients with hematological malignancies. One of the issues to overcome in the treatment of solid tumors using CARs is the lack of a process that generates large amounts of CAR-T cells, reduces cell exhaustion and differentiation, and improves long term survival after infusion into patients. Previously, Torres Chavez et al. demonstrated in a series of in vitro and in vivo experiments, performed in both hematologic and solid tumor models, the profound qualitative impact on CAR-T cell performance after using human platelet lysate (hPL) as a cell growth supplement. T cells expanded with their hPL showed a good proliferative capacity and enhanced long-term in vivo persistence compared to Fetal Bovine Serum (FBS) or human AB Serum (ABS), resulting in superior anti-tumor effects. Additionally, this group demonstrated that the transduction of T cells to generate the CAR-T cells was significantly improved by the use of hPL. Mill Creek's human platelet lysate (hPL) is produced using expired human platelets obtained from accredited blood banks in the United States. These platelets were originally intended for use in patient transfusion. The safety of platelets used in transfusion is managed by the U.S. Food & Drug Administration (FDA), as well as the Association for the Advancement of Blood & Biotherapies (AABB). These organizations set standards, including testing for transmissible diseases. The United States record for blood safety is well established, with extremely low rates of disease transmission, making the platelet units used for hPL manufacture low risk. The Covid-19 pandemic has increased awareness of emerging infectious diseases, even though transmission of Covid-19 via blood transfusion has not been documented. For that reason, we developed gamma irradiated version of our products, which offer an additional safety measure in the clinic. Previously, we have shown that the use of our platelet lysates has the potential of significantly impacting T cell manufacture by improving the quality and potency of the end product. In this study, we compare the phenotypic profile of different subsets of peripheral blood lymphocytes cultured using our different hPL products versus serum derived products. Additionally we establish a protocol for large scale suspension culture, which could be used for expansion of allogeneic CAR cells. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy.
- Author
-
Goldman, Adam, Maor, Elad, Bomze, David, Liu, Jennifer E., Herrmann, Joerg, Fein, Joshua, Steingart, Richard M., Mahmood, Syed S., Schaffer, Wendy L., Perales, Miguel-Angel, and Shouval, Roni
- Subjects
- *
CHIMERIC antigen receptors , *CARDIOVASCULAR diseases , *T cells , *CARDIOMYOPATHIES , *TACHYARRHYTHMIAS , *CYTOKINE release syndrome , *VENTRICULAR arrhythmia , *LUNG disease diagnosis , *CARDIOVASCULAR disease prevention , *LUNG disease prevention , *CARDIOVASCULAR disease diagnosis , *CARDIOTOXICITY , *BIOLOGICAL products , *IMMUNIZATION , *LUNG diseases , *PHARMACOLOGY , *CELL receptors , *DRUG monitoring , *RESEARCH funding , *DRUG side effects - Abstract
Background: Pivotal trials of chimeric antigen receptor T-cell (CAR-T) have identified common toxicities but may have been underpowered to detect cardiovascular and pulmonary adverse events (CPAEs).Objectives: This study sought to investigate CPAEs associated with commercial CD19-directed CAR-T therapy.Methods: In this retrospective, pharmacovigilance study, the authors used the Food and Drug Administration adverse event reporting system to identify CPAEs associated with axicabtagene-ciloleucel and tisagenlecleucel. The authors evaluated disproportionate reporting by the reporting odds ratio (ROR) and the lower bound of the information component 95% credibility interval (IC025 >0 is deemed significant). Significant associations were further adjusted to age and sex (adj.ROR).Results: The authors identified CAR-T reports of 2,657 patients, including 546 CPAEs (20.5%). CPAEs overlapped with cytokine release syndrome in 68.3% (373 of 546) of the reports. Compared with the full database, CAR-T was associated with overreporting of tachyarrhythmias (n = 74 [2.8%], adj.ROR = 2.78 [95% CI: 2.21-3.51]), cardiomyopathy (n = 69 [2.6%], adj.ROR = 3.51 [2.42-5.09]), pleural disorders (n = 46 [1.7%], adj.ROR = 3.91 [2.92-5.23]), and pericardial diseases (n = 11 [0.4%], adj.ROR = 2.26 [1.25-4.09], all IC025 >0). Venous thromboembolic events (VTEs) were associated only with axicabtagene-ciloleucel therapy (n = 28 [1.6%], adj.ROR = 1.80 [1.24-2.62], IC025 >0). Atrial fibrillation (n = 55) was the leading tachyarrhythmia, followed by ventricular arrhythmias (n = 14). Tachyarrhythmias and VTEs were reported more often following axicabtagene-ciloleucel than tisagenlecleucel in an age- and sex-adjusted model (adj.ROR = 1.82 [1.04-3.18] and adj.ROR = 2.86 [1.18-6.93], respectively). Finally, the fatality rate of CPAEs was 30.9%.Conclusions: In this largest post-marketing study to date, the authors identified an association between CAR-T and various CPAEs, including tachyarrhythmias, cardiomyopathy, pericardial and pleural disorders, and VTEs. These findings should be considered in the multidisciplinary assessment for and monitoring of CAR-T therapy recipients. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
9. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
- Author
-
Rodriguez-Otero, Paula, Ayers, Dieter, Cope, Shannon, Davies, Faith E., Delforge, Michel, Mojebi, Ali, Jansen, Jeroen P., Weisel, Katja, Hege, Kristen, and Dhanasiri, Sujith
- Subjects
- *
TREATMENT effectiveness , *MULTIPLE myeloma , *OVERALL survival , *CHIMERIC antigen receptors , *PROGRESSION-free survival - Abstract
Idecabtagene vicleucel (ide-cel, bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody in the single-arm phase 2 KarMMa clinical trial. Two therapies with distinct mechanisms of action – selinexor plus dexamethasone (Sd) and belantamab mafodotin (BM) – are currently approved in the United States for heavily pretreated patients, including those who are triple-class refractory. To compare ide-cel versus Sd and ide-cel versus BM, matching-adjusted indirect comparisons were performed. Ide-cel extended progression-free survival (PFS) and overall survival (OS) versus both Sd and BM (hazard ratio (HR); 95% confidence interval (CI)). PFS: ide-cel versus Sd, 0.46; 0.28–0.75; ide-cel versus BM, 0.45; 0.27–0.77. OS: ide-cel versus Sd, 0.23; 0.13–0.42; ide-cel versus BM, 0.35; 0.14–0.87. These results suggest ide-cel offers clinically meaningful improvements over currently approved regimens for patients with heavily pretreated RRMM. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
- Author
-
Berdeja, Jesus G, Madduri, Deepu, Usmani, Saad Z, Jakubowiak, Andrzej, Agha, Mounzer, Cohen, Adam D, Stewart, A Keith, Hari, Parameswaran, Htut, Myo, Lesokhin, Alexander, Deol, Abhinav, Munshi, Nikhil C, O'Donnell, Elizabeth, Avigan, David, Singh, Indrajeet, Zudaire, Enrique, Yeh, Tzu-Min, Allred, Alicia J, Olyslager, Yunsi, and Banerjee, Arnob
- Subjects
- *
CHIMERIC antigen receptors , *MULTIPLE myeloma , *CYTOKINE release syndrome , *OVERALL survival , *SURVIVAL rate , *LYMPHOPENIA , *RESEARCH , *IMMUNIZATION , *CLINICAL trials , *RESEARCH methodology , *CELL receptors , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies - Abstract
Background: CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed or refractory multiple myeloma with poor prognosis.Methods: This single-arm, open-label, phase 1b/2 study done at 16 centres in the USA enrolled patients aged 18 years or older with a diagnosis of multiple myeloma and an Eastern Cooperative Oncology Group performance status score of 0 or 1, who received 3 or more previous lines of therapy or were double-refractory to a proteasome inhibitor and an immunomodulatory drug, and had received a proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody. A single cilta-cel infusion (target dose 0·75 × 106 CAR-positive viable T cells per kg) was administered 5-7 days after start of lymphodepletion. The primary endpoints were safety and confirmation of the recommended phase 2 dose (phase 1b), and overall response rate (phase 2) in all patients who received treatment. Key secondary endpoints were duration of response and progression-free survival. This trial is registered with ClinicalTrials.gov, NCT03548207.Findings: Between July 16, 2018, and Oct 7, 2019, 113 patients were enrolled. 97 patients (29 in phase 1b and 68 in phase 2) received a cilta-cel infusion at the recommended phase 2 dose of 0·75 × 106 CAR-positive viable T cells per kg. As of the Sept 1, 2020 clinical cutoff, median follow-up was 12·4 months (IQR 10·6-15·2). 97 patients with a median of six previous therapies received cilta-cel. Overall response rate was 97% (95% CI 91·2-99·4; 94 of 97 patients); 65 (67%) achieved stringent complete response; time to first response was 1 month (IQR 0·9-1·0). Responses deepened over time. Median duration of response was not reached (95% CI 15·9-not estimable), neither was progression-free survival (16·8-not estimable). The 12-month progression-free rate was 77% (95% CI 66·0-84·3) and overall survival rate was 89% (80·2-93·5). Haematological adverse events were common; grade 3-4 haematological adverse events were neutropenia (92 [95%] of 97 patients), anaemia (66 [68%]), leukopenia (59 [61%]), thrombocytopenia (58 [60%]), and lymphopenia (48 [50%]). Cytokine release syndrome occurred in 92 (95%) of 97 patients (4% were grade 3 or 4); with median time to onset of 7·0 days (IQR 5-8) and median duration of 4·0 days (IQR 3-6). Cytokine release syndrome resolved in all except one with grade 5 cytokine release syndrome and haemophagocytic lymphohistiocytosis. CAR T-cell neurotoxicity occurred in 20 (21%) patients (9% were grade 3 or 4). 14 deaths occurred in the study; six due to treatment-related adverse events, five due to progressive disease, and three due to treatment-unrelated adverse events.Interpretation: A single cilta-cel infusion at the target dose of 0·75 × 106 CAR-positive viable T cells per kg led to early, deep, and durable responses in heavily pretreated patients with multiple myeloma with a manageable safety profile. The data from this study formed the basis for recent regulatory submissions.Funding: Janssen Research & Development and Legend Biotech. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
11. EE229 Cost-Effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel in 3L+ Relapsed/Refractory Large B-Cell Lymphoma in the United States Utilizing Real-World Evidence of Chimeric Antigen Receptor T-Cell Therapies.
- Author
-
Locke, F.L., Ray, M., Bradford, R., Jones, C., Dieyi, C., Sun, F., Davies, N., Patel, A., and Oluwole, O.
- Subjects
- *
CHIMERIC antigen receptors , *T cells , *ANTIGEN receptors , *COST effectiveness , *B cells , *LYMPHOMAS , *RITUXIMAB - Published
- 2023
- Full Text
- View/download PDF
12. Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer.
- Author
-
Lundh, Stefan, Jung, In-Young, Dimitri, Alexander, Vora, Anish, Melenhorst, J. Joseph, Jadlowsky, Julie K., and Fraietta, Joseph A.
- Subjects
- *
CD19 antigen , *CHIMERIC antigen receptors , *T cells , *MANUFACTURING cells , *HEMATOLOGIC malignancies , *GENOME editing - Abstract
Chimeric antigen receptor (CAR) T cell therapy has come of age, offering a potentially curative option for patients who are refractory to standard anti-cancer treatments. The success of CAR T cell therapy in the setting of acute lymphoblastic leukemia and specific types of B cell lymphoma led to rapid regulatory approvals of CD19-directed CAR T cells, first in the United States and subsequently across the globe. Despite these major milestones in the field of immuno-oncology, growing experience with CAR T cells has also highlighted the major limitations of this strategy, namely challenges associated with manufacturing a bespoke patient–specific product, intrinsic immune cell defects leading to poor CAR T cell function as well as persistence, and/or tumor cell resistance resulting from loss or modulation of the targeted antigen. In addition, both on- and off-tumor immunotoxicities and the financial burden inherent in conventional cellular biomanufacturing often hamper the success of CAR T cell-based treatment approaches. Herein, we provide an overview of the opportunities and challenges related to the first form of gene transfer therapy to gain commercial approval in the United States. Ongoing advances in the areas of genetic engineering, precision genome editing, toxicity mitigation methods and cell manufacturing will improve the efficacy and safety of CAR T cells for hematologic malignancies and expand the use of this novel class of therapeutics to reach solid tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
- Author
-
Lee, Daniel W., Santomasso, Bianca D., Locke, Frederick L., Ghobadi, Armin, Turtle, Cameron J., Brudno, Jennifer N., Maus, Marcela V., Park, Jae H., Mead, Elena, Pavletic, Steven, Go, William Y., Eldjerou, Lamis, Gardner, Rebecca A., Frey, Noelle, Curran, Kevin J., Peggs, Karl, Pasquini, Marcelo, DiPersio, John F., van den Brink, Marcel R.M., and Komanduri, Krishna V.
- Subjects
- *
RITUXIMAB , *CELL transplantation , *CHIMERIC antigen receptors , *CONSENSUS (Social sciences) , *B cells , *CELLULAR therapy - Abstract
Highlights • Cytokine release syndrome (CRS) and neurotoxicity are common after immune effector cell (IEC) therapy. • Neurotoxicity is now termed IEC-associated neurotoxicity syndrome (ICANS). • A consensus grading system for CRS and ICANS has been developed by experts in the field. • The grading system is designed for IEC therapies in clinical trials and commercial use. • Standardized reporting through the Center for International Blood and Marrow Transplant Research will meet commercial Risk Evaluation and Mitigation Strategies requirements. ABSTRACT Chimeric antigen receptor (CAR) T cell therapy is rapidly emerging as one of the most promising therapies for hematologic malignancies. Two CAR T products were recently approved in the United States and Europe for the treatment ofpatients up to age 25years with relapsed or refractory B cell acute lymphoblastic leukemia and/or adults with large B cell lymphoma. Many more CAR T products, as well as other immunotherapies, including various immune cell- and bi-specific antibody-based approaches that function by activation of immune effector cells, are in clinical development for both hematologic and solid tumor malignancies. These therapies are associated with unique toxicities of cytokine release syndrome (CRS) and neurologic toxicity. The assessment and grading of these toxicities vary considerably across clinical trials and across institutions, making it difficult to compare the safety of different products and hindering the ability to develop optimal strategies for management of these toxicities. Moreover, some aspects of these grading systems can be challenging to implement across centers. Therefore, in an effort to harmonize the definitions and grading systems for CRS and neurotoxicity, experts from all aspects of the field met on June 20 and 21, 2018, at a meeting supported by the American Society for Transplantation and Cellular Therapy (ASTCT; formerly American Society for Blood and Marrow Transplantation, ASBMT) in Arlington, VA. Here we report the consensus recommendations of that group and propose new definitions and grading for CRS and neurotoxicity that are objective, easy to apply, and ultimately more accurately categorize the severity of these toxicities. The goal is to provide a uniform consensus grading system for CRS and neurotoxicity associated with immune effector cell therapies, for use across clinical trials and in the postapproval clinical setting. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods.
- Author
-
Harrison, Richard P., Zylberberg, Ezequiel, Ellison, Simon, and Levine, Bruce L.
- Subjects
- *
MANUFACTURING cells , *CELLULAR therapy , *INDUSTRIAL costs , *CHIMERIC antigen receptors , *MARKET penetration - Abstract
Abstract Cell and gene therapies have demonstrated excellent clinical results across a range of indications with chimeric antigen receptor (CAR)–T cell therapies among the first to reach market. Although these therapies are currently manufactured using patient-derived cells, therapies using healthy donor cells are in development, potentially offering avenues toward process improvement and patient access. An allogeneic model could significantly reduce aggregate cost of goods (COGs), potentially improving market penetration of these life-saving treatments. Furthermore, the shift toward offshore production may help reduce manufacturing costs. In this article, we examine production costs of an allogeneic CAR-T cell process and the potential differential manufacturing costs between regions. Two offshore locations are compared with regions within the United States. The critical findings of this article identify the COGs challenges facing manufacturing of allogeneic CAR-T immunotherapies, how these may evolve as production is sent offshore and the wider implication this trend could have. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy.
- Author
-
Tessema, Frazer A. and Darrow, Jonathan J.
- Subjects
- *
CHIMERIC antigen receptors , *LYMPHOBLASTIC leukemia in children , *T cells , *DRUG approval , *DISEASES in young adults , *DRUG prices , *NEUROTOXICOLOGY , *LEUKEMIA treatment , *CYTOKINES , *ANTIGENS , *ANTINEOPLASTIC agents , *CELL receptors , *GENETIC engineering , *INFECTION , *LYMPHOBLASTIC leukemia , *SYNDROMES , *TUMORS in children , *CHIMERISM , *INDIVIDUALIZED medicine , *ECONOMICS - Abstract
The article discusses the U.S. Food and Drug Administration's approval of the use of drug company Novartis AG's product tisagenlecleucel (Kymriah) to treat B-cell acute lymphoblastic leukemia (ALL) in children and young adults, and it mentions several chimeric antigen receptor T-cell (CAR-T) therapies. Neurotoxicity and acute cytokine release syndrome (cytokine storm) are examined, along with a risk evaluation and mitigation strategy (REMS) and drug prices in America.
- Published
- 2017
- Full Text
- View/download PDF
16. CO99 Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Utilization Patterns for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Among United States (US) Community Hematologists/Oncologists (CH/OS).
- Author
-
Feinberg, B, Klink, A, Schuler, T, Balanean, MPH., A, McAllister, L, Liassou, D, Gajra, A, and Porter, D
- Subjects
- *
DIFFUSE large B-cell lymphomas , *CHIMERIC antigen receptors , *HEMATOLOGISTS , *ONCOLOGISTS , *ANTIGEN receptors - Published
- 2022
- Full Text
- View/download PDF
17. CO5 Completeness of Real-World Data (RWD) in Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in United States (US) Community Oncology/Hematology Practices (CH/OS).
- Author
-
Feinberg, B, Klink, A, Balanean, MPH., A, Schuler, T, McAllister, L, Liassou, D, Gajra, A, and Porter, D
- Subjects
- *
DIFFUSE large B-cell lymphomas , *CHIMERIC antigen receptors , *HEMATOLOGY , *ONCOLOGY - Published
- 2022
- Full Text
- View/download PDF
18. Rethinking mechanisms of neurotoxicity with BCMA directed therapy.
- Author
-
Mohyuddin, Ghulam Rehman, Banerjee, Rahul, Alam, Zakariya, Berger, Katherine E., and Chakraborty, Rajshekhar
- Subjects
- *
BISPECIFIC antibodies , *NEUROTOXICOLOGY , *CHIMERIC antigen receptors , *ANTIBODY-drug conjugates , *PLASMA cells - Abstract
• BCMA-targeted myeloma therapies include CAR-T cells and antibody-based constructs. • Neurotoxicity from BCMA-targeted therapies is generally considered to be off-target. • Unusual peripheral or Parkinsonian neurotoxicities have recently been characterized. • Given BCMA expression on neurons, on-target neurotoxicity may be possible. • Trials of BCMA-targeted therapies should monitor and document such toxicities. B-cell maturation antigen (BCMA) has become a key target for antibody-drug conjugates, bispecific antibodies, chimeric antigen receptor T-cell therapies, and other immunotherapies in multiple myeloma. Some of these agents such as belantamab mafodotin and idecabtagene vicleucel have already received regulatory approval in the United States. Although BCMA has generally been considered to be expressed almost exclusively in plasma cells with a low likelihood of on-target off-tumor toxicity, there has been a range of unusual neurotoxicity observed across the spectrum of BCMA immunotherapies. In certain cases, these unusual neurotoxicity presentations have led to patient death or withdrawal of agents from further development. Our review summarizes the literature in this field and highlights the possibility of on-target toxicities due to neural expression of BCMA. We draw attention to the need for further investigation of these toxicities. This risk becomes increasingly important as BCMA targeted therapies are brought to earlier lines of treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.